Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   35906   clinical trials with a EudraCT protocol, of which   5892   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2010-022557-42
    Sponsor's Protocol Code Number:KF6005/04
    National Competent Authority:Germany - BfArM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2010-12-09
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - BfArM
    A.2EudraCT number2010-022557-42
    A.3Full title of the trial
    A randomized 4-week Phase IIa trial evaluating the efficacy, safety, and tolerability of GRT6005, a new centrally acting analgesic, in subjects with pain due to diabetic polyneuropathy.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A four-week trial evaluating the efficacy, safety and tolerance of GRT6005, a new centrally acting analgesic, in patients with pain due to diabetic nerve damages.
    A.4.1Sponsor's protocol code numberKF6005/04
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGrünenthal GmbH
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGrünenthal GmbH
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGrünenthal GmbH
    B.5.2Functional name of contact pointClinical Development Operations
    B.5.3 Address:
    B.5.3.1Street AddressZieglerstr. 6
    B.5.3.2Town/ cityAachen
    B.5.3.3Post code52078
    B.5.3.4CountryGermany
    B.5.4Telephone number+492415692509
    B.5.6E-mailclinical-trials@grunenthal.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGRT6005 hard capsules (liquid filled with SEDDS_0708)
    D.3.2Product code GRT6005
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 863513-91-1
    D.3.9.2Current sponsor codeGRT6005, M010239FP, Indolyl-Spiroether pure
    D.3.9.3Other descriptive name6’-Fluoro-4’,9’-dihydro-N,N-dimethyl-4-phenyl-spiro[cyclohexane-1,1’(3’H)-pyrano[3,4-b]indol]-4-amin
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGRT6005 hard capsules (liquid filled with SEDDS_0708)
    D.3.2Product code GRT6005
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 863513-91-1
    D.3.9.2Current sponsor codeGRT6005, M010239FP, Indolyl-Spiroether pure
    D.3.9.3Other descriptive name6’-Fluoro-4’,9’-dihydro-N,N-dimethyl-4-phenyl-spiro[cyclohexane-1,1’(3’H)-pyrano[3,4-b]indol]-4-amin
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGRT6005 hard capsules (liquid filled with SEDDS_0708)
    D.3.2Product code GRT6005
    D.3.4Pharmaceutical form Capsule, hard
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 863513-91-1
    D.3.9.2Current sponsor codeGRT6005, M010239FP, Indolyl-Spiroether pure
    D.3.9.3Other descriptive name6’-Fluoro-4’,9’-dihydro-N,N-dimethyl-4-phenyl-spiro[cyclohexane-1,1’(3’H)-pyrano[3,4-b]indol]-4-amin
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboCapsule, hard
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Pain due to diabetic polyneuropathy.
    E.1.1.1Medical condition in easily understood language
    pain due to diabetic nerve damages
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.0
    E.1.2Level LLT
    E.1.2Classification code 10012685
    E.1.2Term Diabetic polyneuropathy
    E.1.2System Organ Class 10029205 - Nervous system disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the analgesic efficacy of fixed doses of 25 µg, 75 µg, and 200 µg GRT6005 once daily compared to placebo in subjects with moderate to severe pain due to diabetic polyneuropathy.
    E.2.2Secondary objectives of the trial
    -To evaluate the safety and tolerability of fixed doses of 25 µg, 75 µg and 200 µg GRT6005 once daily compared to placebo in subjects with moderate to severe pain due to diabetic polyneuropathy.
    -To explore the relationship between exposure to GRT6005 and analgesic efficacy and tolerability.
    -To describe multiple dose kinetics of GRT6005 over 4 weeks in subjects with pain due to DPN.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Subjects must have signed an informed consent form.
    2. Male or female subjects aged 18 years to 75 years inclusive at the Enrollment Visit.
    3. All subjects must have type 1 or type 2 diabetes mellitus and must have a documented clinical diagnosis of painful DPN with symptoms and signs for at least 3 months and pain present at the Enrollment Visit.
    4. The investigator considers the subject’s blood glucose to be controlled by a diet, oral anti-hyperglycemic medication, and/or insulin for at least 3 months prior to enrolling in the trial. This control should be documented.
    Hemoglobin (HbA1C) should not be greater than 11.0% at the Enrollment Visit.
    For Germany only: Hemoglobin (HbA1C) should not be greater than 9.5% at the Enrollment Visit.
    5. Subjects must be using medically acceptable and highly effective methods of birth control:
    For women of childbearing potential: A medically acceptable and highly effective method of birth control is defined as any form of contraception with a low failure rate defined as <1% per year.
    For example:
    - Hormonal contraceptives for at least 2 months prior to the Enrollment Visit and until at least 4 weeks after the Final Visit.
    - An intra-uterine device. Additional barrier contraception must be used by the partner for the duration of the trial, defined as from the time of the Enrollment Visit until 4 weeks after the Final Visit. Women of non-childbearing potential may be included if surgically sterile (i.e., after hysterectomy) or post-menopausal for
    at least 2 years.
    For men: Males have to use barrier contraception (condom) during sexual intercourse and not have sex with women who are pregnant or lactating from the first administration of IMP until 4 weeks after the Final Visit. The male subject has to take care that the female sexual partner uses at least 1 additional method of
    contraception with a low failure rate defined as <1% per year (e.g., oral contraceptives for at least 2 months prior to the Enrollment Visit) during this time frame. A double-barrier method should be supplemented by the use of
    spermicidal agents.
    6. Women of childbearing potential must have a negative urine β-human chorionic gonadotropin (β-hCG) pregnancy test at the Enrollment Visit (Visit 1) and at the Baseline Visit (Visit 3).
    7. Subjects must be on stable analgesic medications for their condition with regular intake for at least 3 months prior to the Enrollment Visit according to their medical history and must be dissatisfied with their current analgesic treatment in terms of
    efficacy and/or tolerability prior to signing the informed consent form.
    8. A daily average pain intensity score ≥4 on the 11-point numeric rating scale (NRS) during the last 3 days prior to the Baseline Visit without intake of rescue medication, during which a subject completed at least 5 of 6 possible pain intensity assessments of these 3 days.
    E.4Principal exclusion criteria
    General:
    1. Concurrent participation in another trial, or within 30 days before the Enrollment Visit of this trial.
    2. Previous participation in this or other trials with GRT6005 (unless enrollment failure due to technical reason).
    3. Previous or current alcohol or drug abuse according to the investigator’s judgment, based on subject’s history, physical examination, or the result of the drug test at the Enrollment Visit or at the Baseline Visit.
    4. Previous or current opioid dependency, based on subject’s history, physical examination, or the result of the drug test at the Enrollment Visit or at the Baseline Visit.
    5. Female subjects who are breastfeeding.
    6. Known or suspected of not being able to comply with the protocol and with the use of the IMP.
    7. Any clinically significant disease that in the investigator's opinion may affect efficacy or safety assessments or may compromise the subject’s safety during trial participation, such as significant pulmonary, gastrointestinal, endocrine, metabolic, neurological, or psychiatric disorders (e.g., major depression and psychosis).
    8. Employees of the investigator, trial site, or sponsor with direct involvement in the proposed trial or other trials under the direction of that investigator, trial site, or sponsor, as well as family members of employees or the investigator.
    9. Subjects with impaired hepatic functionality/cellular integrity determined by bilirubin greater than 2.0 mg/dL and albumin lower than 2.8 g/dL or increased transaminases with alanine aminotransferase or aspartate aminotransferase greater than 3 times the upper limit of normal at the Enrollment or the Prebaseline
    Visit.
    10. History of chronic hepatitis B or C, or human immunodeficiency virus infection, or presence of acute hepatitis A, B, or C within the past 3 months.
    11. Subjects with impaired renal function. Creatinine clearance less than 60 mL/min at the Enrollment Visit or the Pre-baseline Visit (calculated from the Cockcroft-Gault formula).
    12. Any chronic gastrointestinal disease (e.g., celiac disease or colitis ulcerosa) or previous major abdominal surgery (e.g., Billroth procedure or enteroanastomosis) that might affect drug absorption or excretion.
    13. Significant cardiac disease (e.g., unstable angina pectoris, angina pectoris Canadian Cardiovascular Society Class III-IV, acute myocardial infarction within the last 3 months, cardiac insufficiency New York Heart Association Class III-IV).
    14. Presence of risk factors for Torsade de Pointes (e.g., heart failure, hypokalemia, bradycardia).
    15. Marked prolongation of QTc >470 ms at the Enrollment Visit or the Pre-baseline Visit.
    16. History of seizure disorder and/or epilepsy or any condition associated with a significant risk for seizure disorder or epilepsy at the Enrollment Visit at the discretion of the investigator.
    17. History or presence of malignancy within the past 2 years, with the exception of curative treated subjects or subjects being in remission of cancer for at least 2 years and not requiring treatment.
    Trial specific:
    18. Any scheduled surgery or painful procedure during the course of the trial.
    19. Severe or extensive diabetic ulcers or amputations (more than 2 toes) of the limbs or Charcot joints.
    20. Clinically relevant history of hypersensitivity, allergy, or contraindications to any of the IMP’s excipients as well as to opioids or paracetamol.
    21. Significant vascular disease (e.g., peripheral occlusive arterial disease, Fontaine Class III–IV; venous insufficiency, postthrombotic syndrome, Stage III/IV).
    22. Presence of conditions other than painful DPN that could contribute to pain or confound the assessment of self-evaluation of pain, for instance fibromyalgia, complex regional pain syndrome, phantom pain, significant skin conditions such as
    abscesses, significant osteoarthritis, low back pain, inflammation (e.g., rheumatoid arthritis, ankylosing spondylitis), and vasculitis.
    23. Subjects whose body weight is lower than 50 kg.
    24. Conditions that require treatment with prohibited medication (see Section “Concomitant treatments”).
    E.5 End points
    E.5.1Primary end point(s)
    Change from baseline in the pain intensity scores (on an 11-point NRS) during the last week of the 4-week Treatment Period. The pain intensity scores will be evaluated as the mean of the 2 average pain intensity assessments over the last 12 hours.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Complete last week of treatment
    E.5.2Secondary end point(s)
    •Assessment of different responder definitions (rates of 10% to 90% improvement of pain intensity score from baseline) at the treatment visits for Week 1, Week 2, and Week 3, and at the Final Visit.
    •Change from baseline in the pain intensity scores (on an 11-point NRS) during the entire 4-week Treatment Period.
    •Change from baseline in the pain intensity scores (on an 11-point NRS) in the first, second, and third week of the 4-week Treatment Period and in the last 24 hours before the Followup Visit.
    •Weekly mean of current pain intensity (on an 11-point NRS) in the morning and in the evening.
    Quantitative sensory testing (with a selection of tests, i.e., cotton swab testing, brushevoked pain): changes from Baseline to the treatment visit of Week 1 and to the Final Visit.
    • NPS: change from baseline to the treatment visit of Week 1 and to the Final Visit.
    • SF-BPI scores: change from baseline to the Treatment Visit Week 1 and to the Final Visit.
    • PGIC and CGIC at the treatment visit for Week 1 and at the Final Visit.
    • LSEQ at the treatment visit for Week 1 and at the Final Visit.
    • Quality of Life Index – SF-12: Changes from the Baseline Visit to the treatment visit for Week 1 and to the Final Visit.
    • EQ–5D: Changes from the Baseline Visit (Visit 3) to Visit 7.
    • Assessment of rescue medication usage during the Treatment Period.
    Safety and tolerability
    • Frequency of AEs and percentage of subjects discontinuing the trial due to AEs and drugrelated AEs.
    • Time to overall withdrawal and time to withdrawal for specific reasons.
    Endpoints of specific interest
    • Evaluation of plasma concentration of GRT6005 throughout the Treatment and Follow-up Period. Samples will be taken according to Section 2.2 (schedule of events).
    • Assessment of potential withdrawal symptoms using COWS at the Follow-up Visit.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Different responder definitions:V4, V5, V6, V7.Change from baseline in pain intensity scores:EntireTreatmentPeriod.Change from baseline in pain intensity scores:week 1,2,3 of Treatment and last 24 hours before Followup Visit. Weekly mean of current pain intensity:Each morning + evening. Quantitative sensory testing:V3, V4, V7. NPS:V3, V4, V7. SF-BPI:V3, V4, V7. PGIC and CGIC:V3, V4, V7. SF-12:V3, V4, V7. EQ–5D:V3, V4, V7. Rescue medication usage:EntireTreatmentPeriod. Frequency AEs + percentage of subjects discontinuing the trial due to AEs and drugrelated AEs:Entiretime. Time to overall withdrawal and time to withdrawal for specific reasons:Entiretime. Evaluation of plasma concentration of GRT6005:At Treatment and Follow-up Period. Samples see Protocol section 2.2. COWS: V8.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned16
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA24
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    last subject last visit
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months7
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 200
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 200
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state60
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 200
    F.4.2.2In the whole clinical trial 200
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Subjects will return to normal treatment after the end of the trial.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2011-01-10
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2012-01-05
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA